July 2020 | Aurobindo Pharma USA

Aurobindo Receives FDA Approval for Anastrozole Tablets USP, 1 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Anastrozole Tablets USP, 1 mg. Aurobindo’s Anastrozole Tablets USP, 1 mg are an AB-rated generic equivalent to the reference listed drug (RLD), Arimidex Tablets, 1 mg, of ANI Pharmaceuticals, Inc. Anastrozole Tablets […]

Aurobindo Receives FDA Approval for Anastrozole Tablets USP, 1 mg Read More »

Aurobindo Receives FDA Approval for Imatinib Mesylate Tablets 100 mg and 400 mg

Product News / AurobindoUSA

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Imatinib Mesylate Tablets, 100 mg and 400 mg. Aurobindo’s Imatinib Mesylate Tablets, 100 mg and 400 mg are an AB-rated generic equivalent to the reference listed drug (RLD), Gleevec Tablets, 100 mg

Aurobindo Receives FDA Approval for Imatinib Mesylate Tablets 100 mg and 400 mg Read More »

Aurobindo Pharma has received approval for Montelukast Sodium Oral Granules USP, 4mg

East Windsor, NJ–Aurobindo Pharma has received approval from the U.S. Food and Drug Administrationfor its Abbreviated New Drug Application Montelukast Sodium Oral Granules USP, 4mg. Aurobindo’s Montelukast Sodium Oral Granules USP, 4 mg are an AB-rated generic equivalent to the reference listed drug (RLD),SINGULAIR® of Merck & Co Inc. They will be available in 4

Aurobindo Pharma has received approval for Montelukast Sodium Oral Granules USP, 4mg Read More »